trending Market Intelligence /marketintelligence/en/news-insights/trending/YSIrkFWJZutKKXSFnol90A2 content esgSubNav
In This List

Boston Scientific's system for Parkinson's gets expanded FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Boston Scientific's system for Parkinson's gets expanded FDA approval

The U.S. Food and Drug Administration approved Boston Scientific Corp.'s ImageReady MRI labeling for the Vercise Gevia Deep Brain Stimulation System for use in a full-body magnetic resonance imaging environment to treat symptoms of Parkinson's disease.

Boston Scientific said the system, along with the Vercise Cartesia Directional Lead, treats the symptoms of Parkinson's — such as tremors, muscle stiffness and slowness of movement — by delivering targeted electrical stimulation in the brain. The treatment provides relief from symptoms and better control of unwanted side effects.

The Marlborough, Mass.-based medical-device maker said in an Aug. 19 press release that the FDA approval allows patients to undergo a full-body MRI while benefiting from deep brain stimulation therapy.

In December 2017, the FDA had approved the Vercise Deep Brain Stimulation System to treat symptoms of Parkinson's disease.

The Vercise Gevia with Cartesia Directional Lead was approved by the FDA in January. The ImageReady MRI Vercise Gevia System has been commercially available in the European market since 2017.